Ingevity (NGVT) Stock Forecast, Price Target & Predictions
NGVT Stock Forecast
Ingevity stock forecast is as follows: an average price target of $53.33 (represents a 37.38% upside from NGVT’s last price of $38.82) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
NGVT Price Target
The average price target for Ingevity (NGVT) is $53.33 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $62.00 to $42.00. This represents a potential 37.38% upside from NGVT's last price of $38.82.
NGVT Analyst Ratings
According to 4 Wall Street analysts, Ingevity's rating consensus is 'Buy'. The analyst rating breakdown for NGVT stock is 0 'Strong Buy' (0.00%), 2 'Buy' (50.00%), 2 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Ingevity Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 05, 2024 | John McNulty | BMO Capital | $42.00 | $35.63 | 17.88% | 8.19% |
| Jul 10, 2024 | John McNulty | BMO Capital | $45.00 | $40.62 | 10.78% | 15.92% |
| May 07, 2024 | Chris Kapsch | Loop Capital Markets | $56.00 | $53.85 | 3.99% | 44.26% |
| Apr 22, 2024 | Daniel Rizzo | Jefferies | $62.00 | $44.44 | 39.51% | 59.71% |
| Feb 02, 2023 | Christopher Kapsch | Loop Capital Markets | $100.00 | $87.00 | 14.94% | 157.60% |
The latest Ingevity stock forecast, released on Aug 05, 2024 by John McNulty from BMO Capital, set a price target of $42.00, which represents a 17.88% increase from the stock price at the time of the forecast ($35.63), and a 8.19% increase from NGVT last price ($38.82).
Ingevity Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 4 |
| Avg Price Target | - | $43.50 | $51.25 |
| Last Closing Price | $38.82 | $38.82 | $38.82 |
| Upside/Downside | -100.00% | 12.06% | 32.02% |
In the current month, the average price target of Ingevity stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Ingevity's last price of $38.82. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 07, 2024 | CJS Securities | - | Outperform | Upgrade |
| Aug 05, 2024 | BMO Capital | Market Perform | Market Perform | Hold |
| Jul 10, 2024 | BMO Capital | Market Perform | Market Perform | Hold |
| May 07, 2024 | Loop Capital Markets | Hold | Hold | Hold |
| May 02, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Aug 07, 2023 | BMO Capital | - | Perform | Downgrade |
| Jul 27, 2023 | Loop Capital Markets | - | Buy | Upgrade |
Ingevity's last stock rating was published by CJS Securities on Aug 07, 2024. The company Upgrade its NGVT rating from "null" to "Outperform".
Ingevity Financial Forecast
Ingevity Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $446.00M | $481.80M | $392.60M | $383.60M | $482.00M | - | $382.80M | $336.00M | $376.80M | $358.40M | $320.30M | $325.60M | $331.70M | $270.60M | $288.20M | $303.40M | $359.90M |
| Avg Forecast | $328.03M | $388.96M | $428.74M | $331.96M | $317.70M | $397.70M | $418.25M | $311.85M | $318.15M | $377.48M | $407.58M | $319.15M | $332.72M | $464.28M | $486.43M | $411.22M | $392.90M | $422.62M | $409.67M | $341.58M | $289.44M | $354.29M | $337.64M | $291.78M | $282.63M | $317.02M | $256.30M | $264.74M | $305.50M | $365.40M |
| High Forecast | $347.56M | $412.12M | $454.28M | $351.72M | $336.62M | $421.38M | $443.16M | $330.42M | $337.10M | $399.96M | $431.85M | $338.16M | $340.19M | $490.00M | $515.40M | $435.71M | $416.30M | $447.79M | $409.67M | $351.66M | $297.98M | $364.74M | $347.60M | $300.39M | $290.97M | $326.38M | $263.86M | $272.55M | $314.51M | $376.18M |
| Low Forecast | $305.62M | $362.39M | $399.45M | $309.27M | $295.99M | $370.53M | $389.67M | $290.54M | $296.41M | $351.68M | $379.73M | $297.34M | $325.25M | $448.00M | $453.20M | $383.12M | $366.06M | $393.75M | $409.67M | $329.29M | $279.03M | $341.54M | $325.50M | $281.29M | $272.47M | $305.62M | $247.08M | $255.21M | $294.51M | $352.25M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 6 | 3 | 3 | 4 | 4 | 2 | 2 | 3 | 3 | 3 | 16 | 11 | 8 | 8 | 12 | 7 | 12 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.96% | 0.99% | 0.95% | 0.98% | 1.14% | - | 1.12% | 1.16% | 1.06% | 1.06% | 1.10% | 1.15% | 1.05% | 1.06% | 1.09% | 0.99% | 0.98% |
Ingevity's average Quarter revenue forecast for Dec 23 based on 2 analysts is $332.72M, with a low forecast of $325.25M, and a high forecast of $340.19M. NGVT's average Quarter revenue forecast represents a -25.40% decrease compared to the company's last Quarter revenue of $446.00M (Sep 23).
Ingevity EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 6 | 3 | 3 | 4 | 4 | 2 | 2 | 3 | 3 | 3 | 16 | 11 | 8 | 8 | 12 | 7 | 12 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $89.00M | $101.30M | $122.30M | $73.20M | $138.20M | - | $117.90M | $77.90M | $31.20M | $113.90M | $101.80M | $106.90M | $122.90M | $60.70M | $91.90M | $97.00M | $111.00M |
| Avg Forecast | $91.39M | $108.36M | $119.44M | $92.48M | $88.51M | $110.80M | $116.52M | $86.88M | $88.63M | $105.16M | $113.55M | $79.62M | $92.69M | $129.34M | $135.52M | $72.38M | $109.46M | $31.57M | $114.13M | $57.22M | $77.90M | $28.70M | $81.90M | $78.08M | $55.43M | $100.43M | $57.66M | $60.65M | $87.30M | $107.06M |
| High Forecast | $96.83M | $114.81M | $126.56M | $97.99M | $93.78M | $117.39M | $123.46M | $92.05M | $93.91M | $111.42M | $120.31M | $95.54M | $94.77M | $136.51M | $143.59M | $86.86M | $115.98M | $37.89M | $114.13M | $68.66M | $93.48M | $34.44M | $98.27M | $93.70M | $66.52M | $120.51M | $69.20M | $72.78M | $104.76M | $128.48M |
| Low Forecast | $85.14M | $100.96M | $111.28M | $86.16M | $82.46M | $103.23M | $108.56M | $80.94M | $82.58M | $97.98M | $105.79M | $63.69M | $90.61M | $124.81M | $126.26M | $57.90M | $101.98M | $25.26M | $114.13M | $45.77M | $62.32M | $22.96M | $65.52M | $62.46M | $44.34M | $80.34M | $46.13M | $48.52M | $69.84M | $85.65M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.69% | 0.75% | 1.69% | 0.67% | 4.38% | - | 2.06% | 1.00% | 1.09% | 1.39% | 1.30% | 1.93% | 1.22% | 1.05% | 1.52% | 1.11% | 1.04% |
2 analysts predict NGVT's average Quarter EBITDA for Dec 23 to be $92.69M, with a high of $94.77M and a low of $90.61M. This is 4.15% upper than Ingevity's previous annual EBITDA (Sep 23) of $89.00M.
Ingevity Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 6 | 3 | 3 | 4 | 4 | 2 | 2 | 3 | 3 | 3 | 16 | 11 | 8 | 8 | 12 | 7 | 12 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $25.20M | $35.50M | $50.70M | $15.60M | $75.40M | - | $60.80M | $29.30M | $-4.20M | $44.30M | $48.70M | $46.00M | $69.90M | $20.20M | $45.30M | $44.30M | $59.90M |
| Avg Forecast | $31.97M | $63.95M | $70.13M | $29.43M | $32.52M | $54.50M | $58.50M | $26.16M | $16.86M | $32.70M | $38.30M | $41.16M | $-3.46M | $44.12M | $49.88M | $37.42M | $31.46M | $-4.25M | $58.85M | $29.58M | $29.30M | $-3.86M | $31.85M | $37.35M | $23.85M | $57.12M | $19.19M | $29.90M | $39.87M | $57.78M |
| High Forecast | $34.45M | $68.90M | $75.56M | $31.71M | $35.04M | $58.72M | $63.03M | $28.19M | $18.16M | $39.24M | $41.26M | $49.40M | $799.32K | $50.68M | $53.74M | $44.90M | $33.89M | $-3.40M | $58.85M | $35.50M | $35.16M | $-3.09M | $38.22M | $44.82M | $28.62M | $68.54M | $23.03M | $35.88M | $47.84M | $69.33M |
| Low Forecast | $29.13M | $58.27M | $63.90M | $26.82M | $29.63M | $49.66M | $53.30M | $23.84M | $15.36M | $26.16M | $34.90M | $32.93M | $-6.66M | $40.11M | $45.45M | $29.94M | $28.66M | $-5.10M | $58.85M | $23.67M | $23.44M | $-4.64M | $25.48M | $29.88M | $19.08M | $45.70M | $15.35M | $23.92M | $31.90M | $46.22M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.57% | 0.71% | 1.35% | 0.50% | -17.74% | - | 2.06% | 1.00% | 1.09% | 1.39% | 1.30% | 1.93% | 1.22% | 1.05% | 1.52% | 1.11% | 1.04% |
Ingevity's average Quarter net income forecast for Dec 23 is $-3.46M, with a range of $-6.66M to $799.32K. NGVT's average Quarter net income forecast represents a -113.74% decrease compared to the company's last Quarter net income of $25.20M (Sep 23).
Ingevity SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 6 | 3 | 3 | 4 | 4 | 2 | 2 | 3 | 3 | 3 | 16 | 11 | 8 | 8 | 12 | 7 | 12 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $40.00M | $51.70M | $48.60M | $55.90M | $54.20M | - | $40.00M | $48.30M | $43.50M | $47.50M | $40.00M | $41.50M | $34.90M | $34.50M | $38.50M | $40.80M | $40.70M |
| Avg Forecast | $38.10M | $45.18M | $49.80M | $38.56M | $36.90M | $46.20M | $48.58M | $36.22M | $36.96M | $43.85M | $47.34M | $27.08M | $38.65M | $53.93M | $56.50M | $24.62M | $45.64M | $44.02M | $47.59M | $19.46M | $48.30M | $40.02M | $34.15M | $30.68M | $21.52M | $28.52M | $32.77M | $25.41M | $36.72M | $39.26M |
| High Forecast | $40.37M | $47.87M | $52.77M | $40.86M | $39.10M | $48.95M | $51.48M | $38.38M | $39.16M | $46.46M | $50.16M | $32.50M | $39.52M | $56.92M | $59.87M | $29.54M | $48.36M | $52.83M | $47.59M | $23.35M | $57.96M | $48.02M | $40.98M | $36.82M | $25.82M | $34.22M | $39.33M | $30.49M | $44.06M | $47.11M |
| Low Forecast | $35.50M | $42.09M | $46.40M | $35.92M | $34.38M | $43.04M | $45.26M | $33.75M | $34.43M | $40.85M | $44.11M | $21.66M | $37.78M | $52.04M | $52.64M | $19.70M | $42.52M | $35.22M | $47.59M | $15.57M | $38.64M | $32.02M | $27.32M | $24.54M | $17.21M | $22.82M | $26.22M | $20.33M | $29.38M | $31.41M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.74% | 0.92% | 1.97% | 1.22% | 1.23% | - | 2.06% | 1.00% | 1.09% | 1.39% | 1.30% | 1.93% | 1.22% | 1.05% | 1.52% | 1.11% | 1.04% |
Ingevity's average Quarter SG&A projection for Dec 23 is $38.65M, based on 2 Wall Street analysts, with a range of $37.78M to $39.52M. The forecast indicates a -3.38% fall compared to NGVT last annual SG&A of $40.00M (Sep 23).
Ingevity EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 6 | 3 | 3 | 4 | 4 | 2 | 2 | 3 | 3 | 3 | 16 | 11 | 8 | 8 | 12 | 7 | 12 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.70 | $0.98 | $1.36 | $0.42 | $1.99 | - | $1.56 | $0.75 | $-0.11 | $1.11 | $1.21 | $1.24 | $1.69 | $0.49 | $1.09 | $1.06 | $1.42 |
| Avg Forecast | $0.88 | $1.76 | $1.93 | $0.81 | $0.90 | $1.50 | $1.61 | $0.72 | $0.46 | $0.90 | $1.05 | $0.34 | $-0.10 | $1.21 | $1.37 | $1.13 | $0.87 | $1.69 | $1.62 | $1.04 | $0.78 | $1.54 | $1.32 | $1.03 | $0.78 | $1.01 | $0.60 | $0.80 | $1.01 | $1.41 |
| High Forecast | $0.95 | $1.90 | $2.08 | $0.87 | $0.96 | $1.62 | $1.73 | $0.78 | $0.50 | $1.08 | $1.14 | $0.36 | $0.02 | $1.39 | $1.48 | $1.22 | $0.93 | $1.82 | $1.62 | $1.08 | $0.80 | $1.60 | $1.37 | $1.07 | $0.81 | $1.05 | $0.63 | $0.84 | $1.04 | $1.47 |
| Low Forecast | $0.80 | $1.60 | $1.76 | $0.74 | $0.82 | $1.37 | $1.47 | $0.66 | $0.42 | $0.72 | $0.96 | $0.31 | $-0.18 | $1.10 | $1.25 | $1.03 | $0.79 | $1.54 | $1.62 | $0.99 | $0.74 | $1.47 | $1.26 | $0.98 | $0.74 | $0.97 | $0.58 | $0.77 | $0.96 | $1.35 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.58% | 0.71% | 1.20% | 0.49% | 1.18% | - | 1.51% | 0.97% | -0.07% | 0.84% | 1.17% | 1.60% | 1.67% | 0.81% | 1.35% | 1.05% | 1.00% |
According to 2 Wall Street analysts, Ingevity's projected average Quarter EPS for Dec 23 is $-0.10, with a low estimate of $-0.18 and a high estimate of $0.02. This represents a -113.62% decrease compared to NGVT previous annual EPS of $0.70 (Sep 23).
Ingevity Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| OEC | Orion Engineered Carbons | $17.20 | $32.00 | 86.05% | Buy |
| ECVT | Ecovyst | $6.58 | $10.00 | 51.98% | Buy |
| NGVT | Ingevity | $38.82 | $53.33 | 37.38% | Buy |
| MTX | Minerals | $71.61 | $90.00 | 25.68% | Buy |
| KWR | Quaker Chemical | $169.26 | $197.50 | 16.68% | Buy |
| SXT | Sensient | $76.67 | $85.00 | 10.86% | - |
| FUL | H.B. Fuller Company | $81.66 | $85.60 | 4.82% | Buy |
| ESI | Element Solutions | $25.69 | $25.60 | -0.35% | Buy |
NGVT Forecast FAQ
Is Ingevity a good buy?
Yes, according to 4 Wall Street analysts, Ingevity (NGVT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 50.00% of NGVT's total ratings.
What is NGVT's price target?
Ingevity (NGVT) average price target is $53.33 with a range of $42 to $62, implying a 37.38% from its last price of $38.82. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Ingevity stock go up soon?
According to Wall Street analysts' prediction for NGVT stock, the company can go up by 37.38% (from the last price of $38.82 to the average price target of $53.33), up by 59.71% based on the highest stock price target, and up by 8.19% based on the lowest stock price target.
Can Ingevity stock reach $60?
NGVT's highest twelve months analyst stock price target of $62 supports the claim that Ingevity can reach $60 in the near future.
What are Ingevity's analysts' financial forecasts?
Ingevity's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.45B (high $1.53B, low $1.35B), average EBITDA is $402.7M (high $426.69M, low $375.19M), average net income is $171.68M (high $184.97M, low $156.43M), average SG&A $167.91M (high $177.9M, low $156.43M), and average EPS is $4.72 (high $5.09, low $4.31). NGVT's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $1.48B (high $1.57B, low $1.38B), average EBITDA is $411.67M (high $436.19M, low $383.54M), average net income is $195.48M (high $210.62M, low $178.12M), average SG&A $171.64M (high $181.87M, low $159.92M), and average EPS is $5.38 (high $5.8, low $4.9).
Did the NGVT's actual financial results beat the analysts' financial forecasts?
Based on Ingevity's last annual report (Dec 2022), the company's revenue was $1.67B, beating the average analysts forecast of $1.57B by 6.48%. Apple's EBITDA was $451.5M, beating the average prediction of $312.38M by 44.54%. The company's net income was $211.6M, beating the average estimation of $115.64M by 82.98%. Apple's SG&A was $198.8M, beating the average forecast of $156.71M by 26.86%. Lastly, the company's EPS was $5.54, beating the average prediction of $5.22 by 6.17%. In terms of the last quarterly report (Sep 2023), Ingevity's revenue was $446M, missing the average analysts' forecast of $464.28M by -3.94%. The company's EBITDA was $89M, missing the average prediction of $129.34M by -31.19%. Ingevity's net income was $25.2M, missing the average estimation of $44.12M by -42.88%. The company's SG&A was $40M, missing the average forecast of $53.93M by -25.83%. Lastly, the company's EPS was $0.7, missing the average prediction of $1.21 by -42.35%